Logo image of CORV.CA

Correvio Pharma Corp (CORV.CA) Stock Price, Quote, News and Overview

TSX:CORV - Toronto Stock Exchange -

0.56  0 (0%)

CORV.CA Quote, Performance and Key Statistics

Correvio Pharma Corp

TSX:CORV (5/29/2020, 3:31:13 PM)

0.56

0 (0%)

Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
Statistics
52 Week High3.66
52 Week Low0.36
Market Cap37.07M
Shares66.19M
FloatN/A
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A N/A


CORV.CA short term performance overview.The bars show the price performance of CORV.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

CORV.CA long term performance overview.The bars show the price performance of CORV.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CORV.CA is 0.56 null. In the past month the price increased by 1.82%. In the past year, price decreased by -81.33%.

Correvio Pharma Corp / CORV Daily stock chart

About CORV.CA

Company Profile

Correvio Pharma Corp, formerly Cardiome Pharma Corp is a specialty pharmaceutical company. It is engaged in the development and commercialization of cardiovascular therapies. The company's products include AGGRASTAT, EXEMBOL, BRINAVESS and others.

Company Info

Correvio Pharma Corp

1441 Creekside Drive

Vancouver BC V6J 4S7

CEO: William L. Hunter

Phone: +1 604 677-6905

Correvio Pharma Corp / CORV.CA FAQ

What is the stock price of Correvio Pharma Corp today?

The current stock price of CORV.CA is 0.56 null.


What is the ticker symbol for Correvio Pharma Corp stock?

The exchange symbol of Correvio Pharma Corp is CORV and it is listed on the Toronto Stock Exchange exchange.


On which exchange is CORV.CA stock listed?

CORV.CA stock is listed on the Toronto Stock Exchange exchange.


What is Correvio Pharma Corp worth?

Correvio Pharma Corp (CORV.CA) has a market capitalization of 37.07M null. This makes CORV.CA a Nano Cap stock.


What are the support and resistance levels for Correvio Pharma Corp (CORV.CA) stock?

Correvio Pharma Corp (CORV.CA) has a support level at 0.55 and a resistance level at 0.59. Check the full technical report for a detailed analysis of CORV.CA support and resistance levels.


Should I buy Correvio Pharma Corp (CORV.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Correvio Pharma Corp (CORV.CA) stock pay dividends?

CORV.CA does not pay a dividend.


What is the Price/Earnings (PE) ratio of Correvio Pharma Corp (CORV.CA)?

Correvio Pharma Corp (CORV.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).


CORV.CA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CORV.CA. When comparing the yearly performance of all stocks, CORV.CA is a bad performer in the overall market: 92.21% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CORV.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CORV.CA. CORV.CA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CORV.CA Financial Highlights

Over the last trailing twelve months CORV.CA reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS decreased by -68.09% compared to the year before.


Industry RankSector Rank
PM (TTM) -107.81%
ROA -59.74%
ROE N/A
Debt/Equity -32.66
Chartmill High Growth Momentum
EPS Q2Q%61.11%
Sales Q2Q%26.59%
EPS 1Y (TTM)-68.09%
Revenue 1Y (TTM)13.81%

CORV.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 60% to CORV.CA. The Buy consensus is the average rating of analysts ratings from 2 analysts.


Ownership
Inst Owners5.18%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts60
Price TargetN/A
EPS Next Y-10.13%
Revenue Next YearN/A